- Home
- WOOF vs ELVN Comparison
WOOF vs ELVN Comparison
Compare WOOF & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOOF
- ELVN
- Stock Information
- Founded
- WOOF 1965
- ELVN 2016
- Country
- WOOF United States
- ELVN United States
- Employees
- WOOF N/A
- ELVN N/A
- Industry
- WOOF Other Specialty Stores
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- WOOF Consumer Discretionary
- ELVN Health Care
- Exchange
- WOOF Nasdaq
- ELVN Nasdaq
- Market Cap
- WOOF 1.0B
- ELVN 1.1B
- IPO Year
- WOOF 2021
- ELVN 2020
- Fundamental
- Price
- WOOF $2.96
- ELVN $21.07
- Analyst Decision
- WOOF Buy
- ELVN Strong Buy
- Analyst Count
- WOOF 10
- ELVN 5
- Target Price
- WOOF $3.85
- ELVN $38.20
- AVG Volume (30 Days)
- WOOF 5.3M
- ELVN 238.7K
- Earning Date
- WOOF 03-26-2025
- ELVN 03-13-2025
- Dividend Yield
- WOOF N/A
- ELVN N/A
- EPS Growth
- WOOF N/A
- ELVN N/A
- EPS
- WOOF N/A
- ELVN N/A
- Revenue
- WOOF $6,116,462,000.00
- ELVN N/A
- Revenue This Year
- WOOF $5.01
- ELVN N/A
- Revenue Next Year
- WOOF $2.13
- ELVN N/A
- P/E Ratio
- WOOF N/A
- ELVN N/A
- Revenue Growth
- WOOF N/A
- ELVN N/A
- 52 Week Low
- WOOF $1.41
- ELVN $15.96
- 52 Week High
- WOOF $6.29
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- WOOF 57.93
- ELVN 49.71
- Support Level
- WOOF $2.39
- ELVN $20.23
- Resistance Level
- WOOF $3.42
- ELVN $22.69
- Average True Range (ATR)
- WOOF 0.21
- ELVN 1.14
- MACD
- WOOF 0.10
- ELVN 0.09
- Stochastic Oscillator
- WOOF 59.65
- ELVN 49.22
About WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet health and wellness company focused on improving the lives of pets, pet parents, and its partners with approximately 1,423 pet care centers offering pet care products such as puppy food, treats, nutrition, and supplies through retail outlets and online platforms. The company generates revenue from the sale of products and services such as dog and cat food, supplies, and companion animals, among others.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.